Study #2021-0404
A Phase 1 Study of TAS2940 in Patients with Locally Advanced or Metastatic Solid Tumors with EGFR and/or HER2 Aberrations
MD Anderson Study Status
Not Accepting
Treatment Agent
TAS2940
Description
This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of TAS2940 in patients with advanced or metastatic solid tumors who are not candidates for approved or available therapies.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Tumor, Glioblastoma, Non-small Cell Lung Cancer, Breast Cancer
Study phase:
Phase I
Physician name:
Jordi Rodon Ahnert
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-794-1615
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.